Abstract：Objective To study the relationship between changes in prostate volume and neoadjuvant hormone therapy (NHT) duration in prostate cancer radiotherapy. Methods Fifty patients with prostate cancer who received NHT were enrolled in the study continuously. The diameters along the x-, y-, and z-axes of the prostate were measured, and the volume of prostate was calculated weekly during radiotherapy. The relationship of prostate volume reduction with NHT duration, prostate volume before radiotherapy, and prostate cancer risk groups was analyzed during radiotherapy. Results The prostate volume in all patients decreased after radiotherapy. Patients with short NHT duration had larger changes in prostate volume and diameters than those with long NHT duration. Compared with those with a large prostate volume, patients with a normal prostate volume had larger changes in prostate volume and diameters long three axes after 7 weeks of radiotherapy, shorter NHT duration before radiotherapy, and lower risk of prostate cancer. In patients with low-and medium-risk prostate cancer, the prostate volumes were significantly reduced to 68.10% and 78.70%, respectively, of those before radiotherapy after no more than 4 months of NHT (P=0.002), but remained similar after more than 4 months of NHT. In patients with high-risk and more severe prostate cancer, the prostate volumes were significantly reduced to 76.59% and 85.46%, respectively, of those before radiotherapy after no more than 6 months of NHT (P=0.001), but remained similar after more than 6 months of NHT. Conclusions The changes in prostate volume and diameters along three axes during radiotherapy become smaller with longer NHT duration. Patients with low-or medium-risk prostate cancer have slight changes in prostate volume after more than 4 months of NHT, while patients with high-risk or locally advanced prostate cancer have slight changes in prostate volume after more than 6 months of NHT.
Li Hongzhen,Gao Xianshu,Ji Chen et al. Relationship between prostate volume reduction and neoadjuvant hormone therapy duration in prostate cancer radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 511-515.
[1] Kupelian PA,Willoughby TR,Meeks SL,et al. Intraprostatic fiducials for localization of the prostate gland:monitoring intermarker distances during radiation therapy to test for marker stability[J].Int J Radiat Oncol Biol Phys,2005,62(5):1291-1296. [2] Lilleby W,Lilleby W,Lilleby W,et al. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose[J].Acta Oncol,2003,42(1):10-14. [3] Langenhuijsen JF,van Lin EN,Hoffmann AL,et al. Neoadjuvant androgen deprivation for prostate volume reduction:the optimal duration in prostate cancer radiotherapy[J].Urol Oncol,2011,29(1):52-57.DOI:10.1016/j.urolonc.2009.03.024. [4] Zelefsky MJ,Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer:reducing the potential morbidity of therapy[J].Urology,1997,49(1):38-45. [5] Yang FE,Chen GT,Ray P,et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage c prostate cancer[J].Int J Radiat Oncol Biol Phys,1995,33(5):1009-1017. [6] Lilleby W,Foss SD,Knutsen BH,et al. Computed tomography/ magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation[J].Radiother Oncol,2000,57(2):195-200. [7] Forman JD,Kumar R,Haas G,et al. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate:effects on the volume of normal tissue irradiation[J].Cancer Invest,1995,13(1):8-15. [8] Lawton CA,Winter K,Murray K,et al. Updated results of the phase iii radiation therapy oncology group (rtog) trial 85－31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate[J].Int J Radiat Oncol Biol Phys,2001,49(4):937-946. [9] Bolla M,Gonzalez D,Warde P,et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin[J].N Eng J Med,1997,337(5):295-300. [10] Pilepich MV,Winter K,John MJ,et al. Phase Ⅲ radiation therapy oncology group (rtog) trial 86－10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate[J].Int J Radiat Oncol Biol Phys,2001,50(5):1243-1252. [11] Pollack A,Ashoori F,Sikes C,et al. The early supra-additive apoptotic response of r3327-g prostate tumors to androgen ablation and radiation is not sustained with multiple fractions[J].Int J Radiat Oncol Biol Phys,2000,46(1):153-158. [12] Granfors T,Damber JE,Bergh A,et al. Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma[J].Int J Radiat Oncol Biol Phys,1997,39(5):1031-1036. [13] Lee AK. Radiation therapy combined with hormone therapy for prostate cancer[J].Seminars in radiation oncology,2006(1):20-28. [14] Vaillancourt L,Têtu B,Fradet Y,et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma:a randomized study[J].Am J Surg Pathol,1996,20(1):86-93.
2015, Vol. 24 
